This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why Staar Surgical (STAA) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Staar Surgical (STAA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Reasons to Add The Cooper Companies Stock to Your Portfolio Now
by Zacks Equity Research
COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Wall Street Analysts Predict a 43.93% Upside in Staar Surgical (STAA): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Staar Surgical (STAA) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 Stocks to Buy Amid Dental Supplies Industry Challenges
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
Staar Surgical (STAA) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Staar Surgical (STAA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Implied Volatility Surging for STAAR Surgical (STAA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to STAAR Surgical (STAA) stock based on the movements in the options market lately.
Why Staar Surgical (STAA) International Revenue Trends Deserve Your Attention
by Zacks Equity Research
Evaluate Staar Surgical's (STAA) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Staar Surgical (STAA) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Staar Surgical (STAA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 32% and 4.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Becton Dickinson (BDX) Q3 Earnings Beat Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 5.74% and 1.57%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Staar Surgical (STAA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Don't Overlook Staar Surgical (STAA) International Revenue Trends While Assessing the Stock
by Zacks Equity Research
Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Wall Street's Insights Into Key Metrics Ahead of Staar Surgical (STAA) Q1 Earnings
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Staar Surgical (STAA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Dentsply International (XRAY) Meets Q1 Earnings Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 0% and 1.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength?
by Zacks Equity Research
Staar Surgical (STAA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in West Pharmaceutical (WST): Can Its 5.7% Jump Turn into More Strength?
by Zacks Equity Research
West Pharmaceutical (WST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Staar Surgical (STAA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Staar Surgical (STAA) Beats Q4 Earnings Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 26.32% and 0.30%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Key Metrics Tell Us About Staar Surgical (STAA) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Staar Surgical (STAA) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Staar Surgical (STAA) Q2 Earnings Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 25% and 0.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 8.21% and 0.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 8% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?